Firebrick Pharma’s patent application covering the use of Nasodine® Nasal Spray (Nasodine) in COVID-19 has been granted in the US.
The US patent dated 15 February 2022, is titled: “Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes.”
A copy of the patent is available to view on the Investors page of this website.
“This patent covers the use of any povidone-iodine formulation in the nose for reducing the viral load of SARS-CoV-2, the virus that causes COVID-19,” said Firebrick Executive Chairman. Dr Peter Molloy.
“Any person or company promoting or selling a povidone-iodine nasal spray in the US for this or a related purpose is most likely infringing our patent.”
The patent has also been filed in Europe, Japan and other countries and granted as an Innovation Patent in Australia.
We would like to emphasis that Nasodine is not yet approved for sale in Australia or elsewhere and any use in COVID-19 would be strictly subject to additional regulatory approvals for that indication.